Y Li et al. showed that the expression of ADCY1 was downregulated in osteosarcoma compared with benign bone tumors, suggesting that ADCY1 may be potential biomarkers for osteosarcoma tumorigenesis and therapeutics50. This evidence concerns the gene ADCY1 and bone neoplasm.